Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the clinical predictive value of 68Ga-DOTA-BPP in subjects with triple-negative breast cancer. The visual and semiquantitative methods will be used to assess the PET/CT images
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• 18-75 years old;
• ECOG score 0 or 1 point;
• Participants with confirmed TNBC cancer who are suggested by the clinicians to conduct PET/CT imaging for tumor diagnosis or staging.
Locations
Other Locations
China
Ethics Committee of Peking University Cancer Hospital
RECRUITING
Beijing
Contact Information
Primary
Qian Zhang
1806708691@qq.com
13765839835
Backup
Hua Zhu, M.D
zhuhuabch@pku.edu
13671224863
Time Frame
Start Date: 2022-10-01
Estimated Completion Date: 2024-10
Participants
Target number of participants: 20
Treatments
68Ga-DOTA-BPP
68Ga-DOTA-BPP PET/CT: after intravenous injection of 2.96 MBq/ kg body weight of quality-controlled 68Ga-DOTA-BPP, a Siemens Biograph PET/CT scan will be applied within 1 h-2 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
18F-FGD
18F-FDG PET/CT: after intravenous injection of 2.96 MBq/ kg body weight of quality-controlled 18F-FDG, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
Related Therapeutic Areas
Sponsors
Leads: Peking University Cancer Hospital & Institute